Antiretroviral agents

Clinical Virology: Third Edition

Volumn , Issue , 2022, Pages 167-216

  Sobieszczyk, Magdalena E ^a   Taylor, Barbara S ^a   Hammer, Scott M ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Antiretroviral agents; Chemokine receptor 5 (CCR5) inhibitors; Human immunodeficiency virus type 1 (HIV 1); Nonnucleoside reverse transcriptase inhibitors (NNRTIs); Nucleoside analog reverse transcriptase inhibitors (NRTIs); Protease inhibitors (PIs)

Indexed keywords

EID: 77950929973     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1128/9781555815981.ch11     Document Type: Chapter

References (249)

1. Ananworanich, J., A. Hill, U. Siangphoe, K. Ruxrung-Tham, W. Prasithsirikul, P. Chetchotisakd, S. Kierti-Buranakul, W. Munsakul, P. Raksakulkarn, S. Tansuphasawadikul, R. Nuesch, D. A. Cooper, and B. Hirschel. 2005. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir. Ther. 10:761-767.
2. Arenzana-Seisdedos, F., J. L. Virelizier, D. Rousset, I. Clark-Lewis, P. Loetscher, B. Moser, and M. Baggiolini. 1996. HIV blocked by chemokine antagonist. Nature 383:400.
3. Arnaiz, J. A., J. Mallolas, D. Podzamczer, J. Gerstoft, J. D. Lundgren, P. Cahn, G. Fatkenheuer, A. D'Arminio-Monforte, A. Casiro, P. Reiss, D. M. Burger, M. Stek, and J.M. Gatell. 2003. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 17: 831-840.
4. Arribas, J. R., A. L. Pozniak, J. E. Gallant, E. Dejesus, B. Gazzard, R. E. Campo, S. S. Chen, D. McColl, C. B. Holmes, J. Enejosa, J. J. Toole, and A.K. Cheng. 2008. Tenofovir disoproxil fumarate, emtricitabine, and efavi-renz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J. Acquir. Immune Defic. Syndr. 47:74-78.
5. Avinhingsanon, A., W. Monsuthi, P. Kantipong, C. Chuchotaworn, S. Moolphate, N. Yamada, H. Yanai, P. Phanuphak, D. Burger, and K. Ruxrungtham. 2007. Pharmacokinetics and 12 weeks efficacy of nevirapine 600 mg per day in HIV infected patients with active TB receiving rifampicin: a multicenter study, abstr. 576. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
6. Back, D., V. Sekar, and R.M. Hoetelmans. 2008. Da-runavir: pharmacokinetics and drug interactions. Antivir. Ther. 13:1-13.
7. Baxter, J. D., J. M. Schapiro, C. A. Boucher, V. M. Kohlbrenner, D. B. Hall, J. R. Scherer, and D.L. Mayers. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801.
8. Benson, C. A., S. G. Deeks, S. C. Brun, R. M. Gulick, J. J. Eron, H. A. Kessler, R. L. Murphy, C. Hicks, M. King, D. Wheeler, J. Feinberg, R. Stryker, P. E. Sax, S. Riddler, M. Thompson, K. Real, A. Hsu, D. Kempf, A. J. Japour, and E. Sun. 2002. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J. Infect. Dis. 185:599607.
9. Berenguer, J., B. Padilla, V. Estrada, C. Martin, P. Domingo, J. M. Kindelan, and J.M. Ruiz-Guiardin. 2002. Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. AIDS 16:1299-1301.
10. Blum, M. R., S. H. Liao, S. S. Good, and P. de Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85:189-194.
11. Bongiovanni, M., T. Bini, F. Adorni, P. Meraviglia, A. Capetti, F. Tordato, P. Cicconi, E. Chiesa, L. Cordier, A. Cargnel, S. Landonio, S. Rusconi, and A. d'Arminio Monforte. 2003. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir. Ther. 8: 209-214.
12. Borin, M. T., J. H. Chambers, B. J. Carel, W. W. Frei-muth, S. Aksentijevich, and A.A. Piergies. 1997. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antivir. Res. 35:53-63.
13. Boubaker, K., M. Flepp, P. Sudre, H. Furrer, A. Haen-sel, B. Hirschel, K. Boggian, J. P. Chave, E. Bernasconi, M. Egger, M. Opravil, M. Rickenbach, P. Francioli, and A. Telenti. 2001. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin. Infect. Dis. 33:1931-1937.
14. Boucher, C. A., N. Cammack, P. Schipper, R. Schuur-man, P. Rouse, M. A. Wainberg, and J.M. Cameron. 1993. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
15. Boyd, M., C. Duncombe, K. Ruxrungthram, M. Khong-phattanayothin, E. Hassink, P. Srasuebkul, J. Sangkote, P. Reiss, M. Stek, J. Lange, D. A. Cooper, and P. Phan-uphak. 2002. Indinavir TID vs indinavir/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76-week follow up, abstr. 422-W. 9th Conf. Retrovir. Opportunistic Infect., Seattle, WA.
16. Brehm, J., D. Koontz, S. Zelina, N. Sluis-Cremer, and J. Mellors. 2007. 3'-Azido-3'-dideoxythymidine selects mutations in the connection (A371V) and RNase H (Q509L) domains of reverse transcriptase that increase AZT resistance in combination with thymidine analog mutations without affecting the rate of AZT excision on a DNA/DNA template/primer, abstr. 90. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
17. Brown, T. T., S. R. Cole, X. Li, L. A. Kingsley, F. J. Palella, S. A. Riddler, B. R. Visscher, J. B. Margolick, and A.S. Dobs. 2005. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165: 1179-1184.
18. Cahn, P., Haubrich R., J. Leider, G. Pialoux, M. Schechter, S. Walmsley, J. Vingerhoets, M. Peeters, G. De Smedt, M. P. de Bethune, and B. Woodfall. 2007. Pooled 24-week results of DUET-1 and -2: TMC125 (etravirine; ETR) vs placebo in 1203 treatment-experienced HIV-1-infected patients, abstr. H-717. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
19. Calza, L., R. Manfredi, B. Farneti, and F. Chiodo. 2003. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int. J. Antimicrob. Agents 22:54-59.
20. Campo, R., B. da Silva, L. Cotte, J Gathe, B. Gazzard, C. Hicks, M. Dehaan, K. Wikstrom, M. King, and G. Hanna. 2007. Predictors of loss of virologic response in subjects who deintensified to lopinavir/ritonavir monotherapy after achieving plasma HIV-1 RNA <50 copies/ mL on LPV/r plus zidovudine/lamivudine, abstr. 514. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
21. Cardo, D. M., D. H. Culver, C. A. Ciesielski, P. U. Srivastava, R. Marcus, D. Abiteboul, J. Heptonstall, G. Ippolito, F. Lot, P. S. McKibben, and D.M. Bell for The Centers for Disease Control and Prevention Needlestick Surveillance Group. 1997. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N. Engl. J. Med. 337:1485-1490.
22. Carr, A. 2003. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17(Suppl. 1): S141-S148.
23. Carr, A. 2000. HIV protease inhibitor-related lipodystrophy syndrome. Clin. Infect. Dis. 30(Suppl. 2):S135-S142.
24. Carr, A., D. A. Cooper. 2000. Adverse effects of antiretroviral therapy. Lancet 356:1423-1430.
25. Ceccherini-Silberstein, F., V. Svicher, T. Sing, A. Artese, M. M. Santoro, F. Forbici, A. Bertoli, S. Alcaro, G. Palamara, A. d'Arminio Monforte, J. Balzarini, A. Antinori, T. Lengauer, and C.F. Perno. 2007. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J. Virol. 81:11507-11519.
26. Cepeda, J. A., D. Wilks. 2000. Excess peripheral neuropathy in patients treated with hydroxyurea plus di-danosine and stavudine for HIV infection. AIDS 14:332-333.
27. Chamberlain, P. P., J. Ren, C. E. Nichols, L. Douglas, J. Lennerstrand, B. A. Larder, D. I. Stuart, and D.K. Stammers. 2002. Crystal structures of zidovudine-or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J. Virol. 76:10015-10019.
28. Chan-Tack, K. M., M. M. Truffa, K. A. Struble, and D.B. Birnkrant. 2007. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 21:1215-1218.
29. Chi, B. H., M. Sinkala, F. Mbewe, R. A. Cantrell, G. Kruse, N. Chintu, G. M. Aldrovandi, E. M. Stringer, C. Kankasa, J. T. Safrit, and J.S. Stringer. 2007. Singledose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370:1698-1705.
30. Clarke, S. M., F. M. Mulcahy, J. Tjia, H. E. Reynolds, S. E. Gibbons, M. G. Barry, and D.J. Back. 2001. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. 33:1595-1597.
31. Clarke, S. M., F. M. Mulcahy, J. Tjia, H. E. Reynolds, S. E. Gibbons, M. G. Barry, and D.J. Back. 2001. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51:213-217.
32. Clavel, F., A. J. Hance. 2004. HIV drug resistance. N. Engl. J. Med. 350:1023-1035.
33. Clotet, B., N. Bellos, J. M. Molina, D. Cooper, J. C. Goffard, A. Lazzarin, A. Wohrmann, C. Katlama, T. Wilkin, Haubrich R., C. Cohen, C. Farthing, D. Jay-aweera, M. Markowitz, P. Ruane, S. Spinosa-Guzman, and E. Lefebvre. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-1178.
34. Clumeck, N., F. Goebel, W. Rozenbaum, J. Gerstoft, S. Staszewski, J. Montaner, M. Johnson, B. Gazzard, C. Stone, R. Athisegaran, and S. Moore. 2001. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15:1517-1526.
35. Coghlan, M. E., J. P. Sommadossi, N. C. Jhala, W. J. Many, M. S. Saag, and V.A. Johnson. 2001. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin. Infect. Dis. 33:1914-1921.
36. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Ga-bryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Tepplert, K. E. Squires, P. J. Deutsch, and E.A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
37. Connor, E. M., R. S. Sperling, R. Gelber, P. Kiselev, G. Scott, M. J. O'Sullivan, R. VanDyke, M. Bey, W. Shearer, R. L. Jacobson, E. Jimenez, E. O'Neill, B. Bazin, J.-F. Delfraissy, M. Culnane, R. Coombs, M. Elkins, J. Moye, P. Stratton, and J. Balsley for The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:1173-1180.
38. Cooper, D., J. G., J. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, X. Xu, R. Isaacs, H. Teppler, and B.Y. Nguyen. 2008. 48-Week results from BENCHMRK-1, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1, abstr. 788. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
39. Cressey, T. R., H. Green, S. Khoo, J. M. Treluyer, A. Compagnucci, Y. Saidi, M. Lallemant, D. M. Gibb, and D.M. Burger. 2008. Plasma drug concentrations and vi-rologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin. Infect. Dis. 46:1601-1608.
40. Cui, L., R. F. Schinazi, G. Gosselin, J. L. Imbach, C. K. Chu, R. F. Rando, G. R. Revankar, and J.P. Somma-dossi. 1996. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem. Pharmacol. 52:1577-1584.
41. Das, K., A. D. Clark, Jr., P. J. Lewi, J. Heeres, M. R. De Jonge, L. M. Koymans, H. M. Vinkers, F. Daeyaert, D. W. Ludovici, M. J. Kukla, B. De Corte, R. W. Ka-vash, C. Y. Ho, H. Ye, M. A. Lichtenstein, K. Andries, R. Pauwels, M. P. De Bethune, P. L. Boyer, P. Clark, S. H. Hughes, P. A. Janssen, and E. Arnold. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drugresistant HIV-1 variants. J. Med. Chem. 47:2550-2560.
42. De Clercq, E. 2007. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6:1001-1018.
43. DeJesus, E., D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, A. K. Cheng, D. McColl, and B.P. Kearney. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
44. DeJesus, E., G. Herrera, E. Teofilo, J. Gerstoft, C. B. Buendia, J. D. Brand, C. H. Brothers, J. Hernandez, S. A. Castillo, T. Bonny, E. R. Lanier, and T.R. Scott. 2004. Abacavir versus zidovudine combined with lami-vudine and efavirenz, for the treatment of antiretroviralnaive HIV-infected adults. Clin. Infect. Dis. 39:1038-1046.
45. DeJesus, E., S. Walmsley, C. Cohen, D. Cooper, B. Hir-schel, J. Goodrich, H. Valdez, J. Heera, N. Rajicic, and N. Maye. 2008. Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment-naive HIV-infected patients, abstr. 929. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
46. Delaunay, C., F. Brun-Vezinet, R. Landman, G. Collin, G. Peytavin, A. Trylesinski, P. Flandre, M. Miller, and D. Descamps. 2005. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J. Virol. 79:9572-9578.
47. Delehanty, J., C. Wakeford, L. Hulett, J. Quinn, B. McCreedy, M. Almond, D. Miralles, F. Rousseau. 1999. A phase I/II randomized, controlled study of FTC versus 3TC in HIV-infected patients, abstr. 16. 6th Conf. Retrovir. Opportunistic Infect., Chicago, IL.
48. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
49. Descamps, D., V. Joly, P. Flandre, G. Peytavin, V. Meif-fredy, S. Delarue, S. Lastere, J. P. Aboulker, P. Yeni, and F. Brun-Vezinet. 2005. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial (Novavir ANRS 073). J. Clin. Virol. 33:99-103.
50. Doms, R.W. 2007. Understanding HIV entry and targets for therapy. Clinical Care Options HIV. Clinical Care Options, Reston, VA. http://clinicaloptions.com/hiventry.
51. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:47214732.
52. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W.A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
53. Dragsted, U. B., J. Gerstoft, C. Pedersen, B. Peters, A. Duran, N. Obel, A. Castagna, P. Cahn, N. Clumeck, J. N. Bruun, J. Benetucci, A. Hill, I. Cassetti, P. Ver-nazza, M. Youle, Z. Fox, and J.D. Lundgren. 2003. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. 188:635-642.
54. Dronda, F., J. L. Casado, S. Moreno, K. Hertogs, I. Garcia-Arata, A. Antela, M. J. Perez-Elias, L. Ruiz, and B. Larder. 2001. Phenotypic cross-resistance tonelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res. Hum. Retrovir. 17:211-215.
55. Dudley, M. N. 1995. Clinical pharmacokinetics of nucleoside antiretroviral agents. J. Infect. Dis. 171(Suppl. 2):S99-S112.
56. Dufer, M., Y. Neye, P. Krippeit-Drews, and G. Drews. 2004. Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn-Schmiedeberg's Arch. Pharmacol. 369:583-590.
57. Elston, R., J. Scherer, D. Hall, J. Schapiro, R. Bethell, V. Kohlbrenner, and D. Mayers. 2006. De-selection of the I50V mutation occurs in clinical isolates during aptivus/r (tipranavir/ritonavir)-based therapy, abstr. 92. 15th Int. HIV Drug Resistance Workshop, Sitges, Spain.
58. Elston, R. C., D. R. Kuritzkes, and R. Bethell. 2007. An investigation into the influence of the tipranavir-associated V82L/T mutations on the susceptibility to da-runavir and brecanavir, abstr. 602. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
59. Eron, J., Jr., P. Yeni, J. Gathe, Jr., V. Estrada, E. DeJesus, S. Staszewski, P. Lackey, C. Katlama, B. Young, L. Yau, D. Sutherland-Phillips, P. Wannamaker, C. Vavro, L. Patel, J. Yeo, and M. Shaefer. 2006. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368:476-482.
60. Eron, J. J., Jr., R. L. Murphy, D. Peterson, J. Pottage, D. M. Parenti, J. Jemsek, S. Swindells, G. Sepulveda, N. Bellos, B. C. Rashbaum, J. Esinhart, N. Schoellkopf, R. Grosso, and M. Stevens. 2000. A comparison of sta-vudine, didanosine and indinavir with zidovudine, lami-vudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 14:1601-1610.
61. Eshleman, S. H., D. R. Hoover, S. Chen, S. E. Hudel-son, L. A. Guay, A. Mwatha, Fiscus S.A., F. Mmiro, P. Musoke, J. B. Jackson, N. Kumwenda, and T. Taha. 2005. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19:2167-2169.
62. Feng, J. Y., J. Shi, R. F. Schinazi, and K.S. Anderson. 1999. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J. 13:1511-1517.
63. Fischl, M., B. Young, M. Watkins, R. Arduino, E. Jensen, H. Wilson, C. Carey, A. Desai, and J. Schranz. 2001. Direct study: a multicenter, open-label, 24-wk pilot study with a 24-wk extension to evaluate the safety, tolerability and efficacy of indinavir (IDV)-ritonavir (RTV) 800/100 bid in combination with D4T plus 3TC in HIV-infected individuals (Merck Protocol 094), abstr. I-1923. 41st Intersci. Conf. Antimicrob. Agents Chemother.
64. Friedland, G., S. Khoo, C. Jack, and U. Lalloo. 2006. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. An-timicrob. Chemother. 58:1299-1302.
65. Friedland, G. H., R. Pollard, B. Griffith, M. Hughes, G. Morse, R. Bassett, Freimuth W., L. Demeter, E. Con-nick, T. Nevin, M. Hirsch, and Fischl M. for the ACTG 261 Team. 1999. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). J. Acquir. Immune Defic. Syndr. 21:281292.
66. Friend, J., N. Parkin, T. Liegler, J. N. Martin, and S.G. Deeks. 2004. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 18: 1965-1966.
67. Fundaro, C., O. Genovese, C. Rendeli, E. Tamburrini, and E. Salvaggio. 2002. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 16:299300.
68. Gallant, J., A. Pozniak, E. DeJesus, J. Arribas, R. Campo, S.-S. Chen, D. McColl, J. Enejosa, and A. Cheng. 2006. Efficacy and safety of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naive patients, abstr. TUPE0064. XVI Int. AIDS Conf., Toronto, Canada.
69. Gallant, J. E., E. Dejesus, J. R. Arribas, A. L. Pozniak, B. Gazzard, R. E. Campo, B. Lu, D. McColl, S. Chuck, J. Enejosa, J. J. Toole, and A.K. Cheng. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivu-dine, and efavirenz for HIV. N. Engl. J. Med. 354:251260.
70. Gallant, J. E., M. A. Parish, J. C. Keruly, and R.D. Moore. 2005. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis. 40:1194-1198.
71. Gallant, J. E., S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. Suleiman, M. D. Miller, D. F. Coakley, B. Lu, J. J. Toole, and A.K. Cheng. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201.
72. Gathe, J. C., Jr., P. Ive, R. Wood, D. Schurmann, N. C. Bellos, E. DeJesus, A. Gladysz, C. Garris, and J. Yeo. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18: 1529-1537.
73. Gazzard, B. G., A. L. Pozniak, W. Rosenbaum, G. P. Yeni, S. Staszewski, K. Arasteh, K. De Dier, M. Peeters, B. Woodfall, J. Stebbing, and G.A. vant' Klooster. 2003. An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17:F49-F54.
74. Goebel, F., A. Yakovlev, A. L. Pozniak, E. Vinogradova, G. Boogaerts, R. Hoetelmans, M. P. de Bethune, M. Peeters, and B. Woodfall. 2006. Short-term antiviral activity of TMC278-a novel NNRTI-in treatment-naive HIV-1-infected subjects. AIDS 20:1721-1726.
75. Gotte, M., D. Arion, M. A. Parniak, and M.A. Wain-berg. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 74: 3579-3585.
76. Graff, J., N. von Hentig, K. Kuczka, C. Angioni, P. Gute, S. Klauke, E. Babacan, and S. Harder. 2008. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J. An-timicrob. Chemother. 61:394-399.
77. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R.D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1261-1269.
78. Gruzdev, B., A. Rakhmanova, E. Doubovskaya, A. Yakovlev, M. Peeters, A. Rinehart, K. de Dier, P. Baede-Van Dijk, W. Parys, and G. van't Klooster. 2003. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 17:2487-2494.
79. Guillemi, S., Ng F., Zhang W., Lima V., Rocha C., Harris M., Bondy G., Belzberg A., J. Montaner. 2008. Risk factors for reduced bone mineral density in HIV-infected individuals in the modern HAART era, abstr. 969. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
80. Gulick, R. M., Hu X.J., Fiscus S.A., Fletcher C.V., Haubrich R., Cheng H., Acosta E., Lagakos S.W., Swanstrom R., Freimuth W., Snyder S., Mills C., Fischl M., Pettinelli C., Katzenstein D. 2002. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J. Infect. Dis. 186:626-633.
81. Gulick, R. M., Hu X.J., Fiscus S.A., Fletcher C.V., Haubrich R., Cheng H., Acosta E., Lagakos S.W., Swanstrom R., Freimuth W., Snyder S., Mills C., Fischl M., Pettinelli C., Katzenstein D. 2000. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J. Infect. Dis. 182:1375-1384.
82. Gulick, R. M., H. J. Ribaudo, C. M. Shikuma, C. Lalama, B. R. Schackman, W. A. Meyer III, E. P. Acosta, J. Schouten, K. E. Squires, C. D. Pilcher, R. L. Murphy, S. L. Koletar, M. Carlson, R. C. Reichman, B. Bastow, K. L. Klingman, and D.R. Kuritzkes. 2006. Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296:769-781.
83. Gulick, R. M., H. J. Ribaudo, C. M. Shikuma, S. Lustgarten, K. E. Squires, W. A. Meyer III, E. P. Acosta, B. R. Schackman, C. D. Pilcher, R. L. Murphy, W. E. Maher, M. D. Witt, R. C. Reichman, Snyder S., K. L. Klingman, and D.R. Kuritzkes. 2004. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350: 1850-1861.
84. Gulick, R. M., Z. Su, C. Flexner, M. D. Hughes, P. R. Skolnik, T. J. Wilkin, R. Gross, A. Krambrink, E. Coakley, W. L. Greaves, A. Zolopa, R. Reichman, C. Godfrey, M. Hirsch, and D.R. Kuritzkes for the AIDS Clinical Trials Group 5211 Team. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J. Infect. Dis. 196:304-312.
85. Haas, D. W., B. Johnson, J. Nicotera, V. L. Bailey, V. L. Harris, F. B. Bowles, S. Raffanti, J. Schranz, T. S. Finn, A. J. Saah, and J. Stone. 2003. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob. Agents Chemother. 47:2131-2137.
86. Hammer, S. M., M. S. Saag, M. Schechter, J. S. Montaner, R. T. Schooley, D. M. Jacobsen, M. A. Thompson, C. C. Carpenter, M. A. Fischl, B. G. Gazzard, J. M. Gatell, M. S. Hirsch, D. A. Katzenstein, D. D. Rich-man, S. Vella, P. G. Yeni, and P.A. Volberding. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top. HIV Med 14:827-843.
87. Hanna, G. J., V. A. Johnson, D. R. Kuritzkes, D. D. Richman, A. J. Brown, A. V. Savara, J. D. Hazelwood, and R.T. D'Aquila. 2000. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. 181:904-911.
88. Harrigan, P. R., C. Stone, P. Griffin, I. Najera, S. Bloor, S. Kemp, M. Tisdale, B. Larder, and the CNA2001 Investigative Group. 2000. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J. Infect. Dis. 181:912-920.
89. Hartt, J. K., T. Liang, A. Sahagun-Ruiz, J. M. Wang, J. L. Gao, and P.M. Murphy. 2000. The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor. Biochem. Biophys. Res. Commun. 272:699-704.
90. Haubrich, R., D. Berger, P. Chiliade, A. Colson, M. Conant, J. Gallant, T. Wilkin, J. Nadler, G. Pierone, M. Saag, B. van Baelen, and E. Lefebvre. 2007. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 21:F11-F18.
91. Haubrich, R., P. Cahn, B. Grinsztejn, J. Lalezari, J. Madruga, A. Mills, M. Peeters, J. Vingerhoets, K. Ive-son, and G. De Smedt. 2008. DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients, abstr. 790. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
92. Haubrich, R. H., S. Riddler, G. DiRienzo, L. Koma-row, W. Powderly, K. Garren, T. George, J. Rooney, J. Mellors, and D. Havlir. 2007. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection, abstr. 38. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
93. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M.D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
94. Hazuda, D. J., S. D. Young, J. P. Guare, N. J. Anthony, R. P. Gomez, J. S. Wai, J. P. Vacca, L. Handt, S. L. Motzel, H. J. Klein, G. Dornadula, R. M. Dan-ovich, M. V. Witmer, K. A. Wilson, L. Tussey, W. A. Schleif, L. S. Gabryelski, L. Jin, M. D. Miller, D. R. Casimiro, E. A. Emini, and J.W. Shiver. 2004. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528-532.
95. Heera, J., M. Saag, P. Ive, J. Whitcomb, M. Lewis, L. McFadyen, J. Goodrich, H. Mayer, E. van der Ryst, and M. Westby. 2008. Virological correlates associated with treatment failure at week 48 in the phase 3 study of maraviroc in treatment-naive patients, abstr. 40LB. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
96. Hertogs, K., S. Bloor, S. D. Kemp, C. Van den Eynde, T. M. Alcorn, R. Pauwels, M. Van Houtte, S. Stasz-ewski, V. Miller, and B.A. Larder. 2000. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14:1203-1210.
97. Hicks, C., E. DeJesus, D. Wohl, Q. Liao, K. Pappa, and T. Lancaster. 2007. Once-daily fosamprenavir (FPV) boosted with either 100mg or 200mg of ritonavir (r) along with abacavir (ABC)/lamivudine (3TC): 48 week safety and efficacy results from COL100758. 11th Eur. AIDS Conf., Madrid, Spain.
98. Hicks, C. B., P. Cahn, D. A. Cooper, S. L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, and H. Valdez. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466-475.
99. Hu, Z., F. Giguel, H. Hatano, P. Reid, J. Lu, and D.R. Kuritzkes. 2006. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J. Virol. 80:7020-7027.
100. Hunt, P. W., P. R. Harrigan, W. Huang, M. Bates, D. W. Williamson, J. M. McCune, R. W. Price, S. S. Spudich, H. Lampiris, R. Hoh, T. Leigler, J. N. Martin, and S.G. Deeks. 2006. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J. Infect. Dis. 194:926930.
101. Iversen, A. K., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T.C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
102. Ives, K. J., H. Jacobsen, S. A. Galpin, M. M. Garaev, L. Dorrell, J. Mous, K. Bragman, and J.N. Weber. 1997. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J. Antimicrob. Chemother. 39:771-779.
103. Iwamoto, M., L. A. Wenning, G. C. Mistry, A. S. Pe-try, S. Y. Liou, K. Ghosh, S. Breidinger, N. Azrolan, M. J. Gutierrez, W. E. Bridson, J. A. Stone, K. M. Gottesdiener, and J.A. Wagner. 2008. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin. Infect. Dis. 47:137-140.
104. Iwamoto, M., L. A. Wenning, A. S. Petry, T. Laethem, M. Desmet, J. T. Kost, S. Merschman, E. Mangin, N. Azrolan, H. E. Greenberg, W. Haazen, J. A. Stone, K. M. Gottesdiener, and J.A. Wagner. 2006. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of Mk-0518, abstr. A-373. 46th Intersci. Conf. Antimicrob. Agents Chemother.
105. Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Krohn, I. B. Duncan, and J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534.
106. Johnson, M., B. Grinsztejn, C. Rodriguez, J. Coco, E. DeJesus, A. Lazzarin, K. Lichtenstein, V. Wirtz, A. Rightmire, L. Odeshoo, and C. McLaren. 2006. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20:711-718.
107. Johnson, M., T. Campbell, B. Clotet, C. Katlama, A. Lazzarin, W. Towner, M. Peeters, J. Vingerhoets, S. Bollen, and G. De Smedt. 2008. DUET-2: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients, abstr. 791. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
108. Johnson, M. A., J. C. Gathe, Jr., D. Podzamczer, J. M. Molina, C. T. Naylor, Y. L. Chiu, M. S. King, T. J. Podsadecki, G. J. Hanna, and S.C. Brun. 2006. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J. Acquir. Immune Defic. Syndr. 43:153160.
109. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gun-thard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D.D. Richman. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15:119-125.
110. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gun-thard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D.D. Richman. 2008. Update of the drug resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16: 62-68.
111. Joly, V., P. Flandre, V. Meiffredy, N. Leturque, M. Harel, J. P. Aboulker, and P. Yeni. 2002. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 16:2447-2454.
112. Joly, V., M. Moroni, E. Concia, A. Lazzarin, B. Hir-schel, J. Jost, F. Chiodo, Z. Bentwich, W. C. Love, D. A. Hawkins, E. G. L. Wilkins, A. J. Gatell, N. Vetter, C. Greenwald, W. Freimuth W., W. de Cian, and The M/3331/0013B Study Group. 2000. Dela-virdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. Antimicrob. Agents Chemother. 44:3155-3157.
113. Kagan, R. M., M. D. Shenderovich, P. N. Heseltine, and K. Ramnarayan. 2005. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 14:1870-1878.
114. Kakuda, T. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22:685-708.
115. Kassahun, K., I. McIntosh, D. Cui, D. Hreniuk, S. Merschman, K. Lasseter, N. Azrolan, M. Iwamoto, J. A. Wagner, and L.A. Wenning. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. DrugMetab. Dispos. 35:16571663.
116. Katlama, C., T. Campbell, B. Clotet, M. Johnson, A. Lazzarin, K. Arasteh, W. Towner, B. Trottier, M. Pee-ters, J. Vingerhoets, G. De Smedt, B. Baeten, G. Beets, R. Sinha, and B. Woodfall. 2007. DUET-2: 24-week results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1 infected patients, abstr. WESS204-2. 4th IAS Conf. HIV Pathog. Treatment Prev., Sydney, Australia.
117. Kearney, B., R. Price, L. Sheiner, E. Bellibas, S. Sta-prans, L. Thevanayagam, and F. Aweeka. 1999. Estimation of nevirapine exposure within the cerebrospinal fluid using CSF: plasma area under the curve ratios, abstr. 406. Program Abstr. 6th Conf. Retrovir. Opportunistic Infect., Chicago, IL.
118. Kellam, P., C. A. Boucher, and B.A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
119. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7: 165-174.
120. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R.A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
121. Khanlou, H., V. Yeh, B. Guyer, and C. Farthing. 2005. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 19:135-140.
122. Kim, E. Y., L. Vrang, B. Oberg, and T.C. Merigan. 2001. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxy-thymidine for several different multidrug-resistant mutants. AIDS Res. Hum. Retrovir. 17:401-407.
123. Kindberg, E., A. Mickiene, C. Ax, B. Akerlind, S. Vene, L. Lindquist, A. Lundkvist, and L. Svensson. 2008. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J. Infect. Dis. 197:266-269.
124. King, M. S., R. Rode, I. Cohen-Codar, V. Calvez, A. G. Marcelin, G. J. Hanna, and D.J. Kempf. 2007. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 51:3067-3074.
125. Kirk, O., T. L. Katzenstein, J. Gerstoft, L. Mathiesen, H. Nielsen, C. Pedersen, and J.D. Lundgren. 1999. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 13:F9-F16.
126. Kitchen, V. S., C. Skinner, K. Ariyoshi, E. A. Lane, I. B. Duncan, J. Burckhardt, H. U. Burger, K. Bragman, A. J. Pinching, and J.N. Weber. 1995. Safety and activity of saquinavir in HIV infection. Lancet 345:952955.
127. Koh, Y., T. Towata, A. Ghosh, and H. Mitsuya. 2007. Selection in vitro of HIV-1 variants highly resistant to darunavir using a mixture of HIV-1 isolates resistant to multiple PI, abstr. 606. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
128. Kumar, P. N., D. E. Sweet, J. A. McDowell, W. Sym-onds, Y. Lou, S. Hetherington, and S. LaFon. 1999. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 43:603-608.
129. Kuritzkes, D. R., R. L. Bassett, J. D. Hazelwood, H. Barrett, R. A. Rhodes, R. K. Young, and V.A. Johnson. 2004. Rate of thymidine analogue resistance mutation accumulation with zidovudine-or stavudine-based regimens. J. Acquir. Immune Defic. Syndr. 36:600-603.
130. Lafeuillade, A., G. Hittinger, and S. Chadapaud. 2001. Increased mitochondrial toxicity with ribavirin in HIV/ HCV coinfection. Lancet 357:280-281.
131. Lalezari, J. P., K. Henry, M. O'Hearn, J. S. Montaner, P. J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. R. Kuritzkes, J. J. Eron, Jr., J. Chung, R. DeMasi, L. Donatacci, C. Drobnes, J. Delehanty, and M. Salgo. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drugresistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
132. Landman, R., D. Descamps, G. Peytavin, A. Trylesin-ski, C. Katlama, P. M. Girard, B. Bonnet, P. Yeni, M. Bentata, C. Michelet, A. Benalycherif, F. Brun Vezi-net, M. D. Miller, and P. Flandre. 2005. Early virologic failure and rescue therapy of tenofovir, abacavir, and la-mivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin. Trials 6:291-301.
133. Lanier, E. R., M. Ait-Khaled, J. Scott, C. Stone, T. Melby, G. Sturge, M. St. Clair, H. Steel, S. Hether-ington, G. Pearce, W. Spreen, and S. Lafon. 2004. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 9:37-45.
134. Larder, B. A., S. Boor. 2001. Analysis of clinical isolates and site directed mutants reveals the genetic determinants of didanosine resistance, abstr. 47. 5th Int. Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, AZ.
135. Larder, B. A., G. Darby, and D.D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
136. Larder, B. A., K. Hertogs, S. Bloor, C. H. van den Eynde, W. DeCian, Y. Wang, W. Freimuth W., G. Tarpley. 2000. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14: 1943-1948.
137. Larder, B. A., S. D. Kemp, and P.R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696699.
138. Lazzarin, A., T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, W. Towner, B. Trottier, M. Peeters, J. Vingerhoets, G. de Smedt, B. Baeten, G. Beets, R. Sinha, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:39-48.
139. Lederman, M. M., A. Penn-Nicholson, M. Cho, and D. Mosier. 2006. Biology of CCR5 and its role in HIV infection and treatment. JAMA 296:815-826.
140. Lim, J. K., C. Y. Louie, C. Glaser, C. Jean, B. Johnson, H. Johnson, D. H. McDermott, and P.M. Murphy. 2008. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197:262-265.
141. Loeliger, A. E., H. Steel, S. McGuirk, W. S. Powell, and S.V. Hetherington. 2001. The abacavir hypersensitivity reaction and interruptions in therapy. AIDS 15: 1325-1326.
142. Lu, J., S. G. Deeks, R. Hoh, G. Beatty, B. A. Kuritz-kes, J. N. Martin, and D.R. Kuritzkes. 2006. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43:60-64.
143. Ly, T., M. E. Ruiz. 2007. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin. Infect. Dis. 44:e67-e68.
144. MacGregor, T. R., J. P. Sabo, S. H. Norris, P. Johnson, L. Galitz, and S. McCallister. 2004. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials 5:371-382.
145. Madruga, J. V., D. Berger, M. McMurchie, F. Suter, D. Banhegyi, K. Ruxrungtham, D. Norris, E. Lefebvre, M. P. de Bethune, F. Tomaka, M. De Pauw, T. Van-geneugden, and S. Spinosa-Guzman. 2007. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370:49-58.
146. Madruga, J. V., P. Cahn, B. Grinsztejn, Haubrich R., J. Lalezari, A. Mills, G. Pialoux, T. Wilkin, M. Peeters, J. Vingerhoets, G. de Smedt, L. Leopold, R. Trefiglio, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:2938.
147. Maguire, M., D. Shortino, A. Klein, W. Harris, V. Ma-nohitharajah, M. Tisdale, R. Elston, J. Yeo, S. Randall, F. Xu, H. Parker, J. May, and W. Snowden. 2002. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46:731-738.
148. Maitland, D., G. Moyle, J. Hand, S. Mandalia, M. Bof-fito, M. Nelson, and B. Gazzard. 2005. Early virologic failure in HIV-1 infected subjects on didanosine/ tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 19:1183-1188.
149. Mallal, S., D. Nolan, C. Witt, G. Masel, A. M. Martin, C. Moore, D. Sayer, A. Castley, C. Mamotte, D. Maxwell, I. James, and F.T. Christiansen. 2002. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-732.
150. Mallal, S., E. Phillips, G. Carosi, J. M. Molina, C. Workman, J. Tomazic, E. Jagel-Guedes, S. Rugina, O. Kozyrev, J. F. Cid, P. Hay, D. Nolan, S. Hughes, A. Hughes, S. Ryan, N. Fitch, D. Thorborn, and A. Ben-bow. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358:568-579.
151. Marcelin, A. G., B. Masquelier, D. Descamps, J. Izo-pet, C. Charpentier, C. Alloui, G. Peytavin, M. Lavig-non, P. Flandre, and C. Vincent. 2007. Mutations associated with response to boosted tipranavir in HIV-1-infected PI-experienced patients, abstr. 612. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
152. Marcelin, A. G., C. Dalban, G. Peytavin, C. Lamotte, R. Agher, C. Delaugerre, M. Wirden, F. Conan, S. Dantin, C. Katlama, D. Costagliola, and V. Calvez. 2004. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 48:4687-4692.
153. Margot, N. A., E. Isaacson, I. McGowan, A. Cheng, and M.D. Miller. 2003. Extended treatment with ten-ofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J. Acquir. Immune Defic. Syndr. 33:1521.
154. Markowitz, M., J. O. Morales-Ramirez, B. Y. Nguyen, C. M. Kovacs, R. T. Steigbigel, D. A. Cooper, R. Li-porace, R. Schwartz, R. Isaacs, L. R. Gilde, L. Wenning, J. Zhao, and H. Teppler. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
155. Markowitz, M., B. Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J. O. Morales-Ramirez, C. S. Crumpacker, R. D. Isaacs, L. R. Gilde, H. Wan, M. D. Miller, L. A. Wenning, and H. Teppler. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
156. Markowitz, M., L. N. Slater, R. Schwartz, P. H. Ka-zanjian, B. Hathaway, D. Wheeler, M. Goldman, D. Neubacher, D. Mayers, H. Valdez, and S. McCallister. 2007. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase2 study. J. Acquir. Immune Defic. Syndr. 45:401-410.
157. Masquelier, B., D. Breilh, D. Neau, S. Lawson-Ayayi, V. Lavignolle, J. M. Ragnaud, M. Dupon, P. Morlat, F. Dabis, and H. Fleury. 2002. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 46:2926-2932.
158. Matthews, T., M. Salgo, M. Greenberg, J. Chung, R. DeMasi, and D. Bolognesi. 2004. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3:215-225.
159. McCallister, S., H. Valdez, K. Curry, T. MacGregor, M. Borin, Freimuth W., Y. Wang, and D.L. Mayers. 2004. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 35:376-382.
160. McColl, D. J., S. Fransen, S. Gupta, N. Parkin, N. Margot, S. Chuck, A. K. Cheng, and M.D. Miller. 2007. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of el-vitegravir (GS-9137), abstr. 9. 16th Int. HIV Drug Resistance Workshop, Barbados, West Indies.
161. McIntyre, J. A., N. Martinson, G. E. Gray, M. Hopley, T. Kimura, P. Robinson, and D. Mayers. 2005. Addition of short course Combivir to single dose Viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus, abstr. TuFo0204. 3rd Int. AIDS Soc. Conf. HIV Pathog. Treatment, Rio de Janeiro, Brazil.
162. Melby, T., M. Despirito, R. Demasi, G. Heilek-Snyder, M. L. Greenberg, and N. Graham. 2006. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to en-fuvirtide response. J. Infect. Dis. 194:238-246.
163. Merrill, D. P., M. Moonis, T. C. Chou, and M.S. Hirsch. 1996. Lamivudine or stavudine in two-and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J. Infect. Dis. 173:355-364.
164. Miller, M. D., N. Margot, B. Lu, L. Zhong, S. S. Chen, A. Cheng, and M. Wulfsohn. 2004. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 189: 837-846.
165. Miro, J. M., J. Pich, P. Domingo, D. Podzamczer, J. R. Arribas, E. Ribera, J. Arrizabalaga, M. Lonca, E. De Lazzari, and M. Plana. 2007. Immunological reconstitution in severely immunosuppressed antiretroviral-naive patients (<100 CD4b T cells/mm3) using a nonnucleoside reverse transcriptase inhibitor (NNRTI)-or a boosted protease inhibitor (PI)-based antiretroviral therapy regimen: 3 year results (the ADVANZ trial), abstr. P-1915. 17th Eur. Congr. Clin. Microbiol. Infect. Dis. (ECCMID) Int. Cong. Chemother., Munich, Germany.
166. Molina, J. M., A. Wilkin, P. Domingo, R. Myers, J. Hairrell, C. Naylor, T. Podsadecki, M. King, and G. Hanna. 2005. Once daily vs twice daily lopinavir/rito-navir in antiretroviral-naive patients: 96-week results, abstr. WePe12.3C12. 3rd Int. AIDS Soc. Conf. HIV Pathog. Treatment, Rio de Janeiro, Brazil.
167. Molina, J. M., A. G. Marcelin, J. Pavie, L. Heripret, C. M. De Boever, M. Troccaz, G. Leleu, and V. Calvez. 2005. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J. Infect. Dis. 191:840-847.
168. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Cher-nyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D.J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
169. Montaner, J., R. D. Masi, J. Delehanty, J. Chung, Z. Gafoor, and M. Salgo. 2003. Optimizing T-20 treatment: analysis of factors leading to therapeutic success from the registration trials TORO 1 and TORO 2, abstr. 116. 2nd Int. AIDS Soc. Conf. on HIV Pathogenesis and Treatment, Paris, France.
170. Moore, J. P., S. G. Kitchen, P. Pugach, and J.A. Zack. 2004. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 20:111-126.
171. Moore, K. H., G. J. Yuen, R. H. Raasch, J. J. Eron, D. Martin, P. K. Mydlow, and E.K. Hussey. 1996. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin. Pharmacol. Ther. 59:550-558.
172. Moore, R. D., W. M. Wong, J. C. Keruly, and J.C. McArthur. 2000. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 14:273-278.
173. Moyle, G. 2000. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. 22:911-936; discussion, 898.
174. Moyle, G. J., E. DeJesus, P. Cahn, S. A. Castillo, H. Zhao, D. N. Gordon, C. Craig, and T.R. Scott. 2005. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J. Acquir. Immune Defic. Syndr. 38:417-425.
175. Murata, H., P. W. Hruz, and M. Mueckler. 2000. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275:20251-20254.
176. Naeger, L. K., K. A. Struble. 2006. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 20:847-853.
177. Nelson, M., K. Arasteh, B. Clotet, D. A. Cooper, K. Henry, C. Katlama, J. P. Lalezari, A. Lazzarin, J. S. Montaner, M. O'Hearn, P. J. Piliero, J. Reynes, B. Trottier, S. L. Walmsley, C. Cohen, J. J. Eron, Jr., D. R. Kuritzkes, J. Lange, H. J. Stellbrink, J. F. Del-fraissy, N. E. Buss, L. Donatacci, C. Wat, L. Smiley, M. Wilkinson, A. Valentine, D. Guimaraes, R. Demasi, J. Chung, and M.P. Salgo. 2005. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J. Acquir. Immune Defic. Syndr. 40:404-412.
178. Nikolenko, G. N., S. Palmer, F. Maldarelli, J. W. Mel-lors, J. M. Coffin, and V.K. Pathak. 2005. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA 102:20932098.
179. Opravil, M., B. Hirschel, A. Lazzarin, H. Furrer, J. P. Chave, S. Yerly, L. R. Bisset, M. Fischer, P. Vernazza, E. Bernasconi, M. Battegay, B. Ledergerber, H. Gun-thard, C. Howe, R. Weber, and L. Perrin. 2002. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J. Infect. Dis. 185:12511260.
180. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents-January 29, 2008. Department of Health and Human Services, Washington, DC. www.aidsinfo.nih.gov/ContentFiles/AdultAdolescentGL.pdf.
181. Pata, J. D., W. G. Stirtan, S. W. Goldstein, and T.A. Steitz. 2004. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 101:10548-10553.
182. Pereira, A. S., L. M. Smeaton, J. G. Gerber, E. P. Acosta, Snyder S., Fiscus S.A., R. R. Tidwell, R. M. Gulick, R. L. Murphy, and J.J. Eron, Jr. 2002. The pharmacokinetics of amprenavir, zidovudine, and lami-vudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J. Infect. Dis. 186:198-204.
183. Persico, M., E. Persico, C. T. Bakker, I. Rigato, A. Amoroso, R. Torella, P. J. Bosma, C. Tiribelli, and J.D. Ostrow. 2001. Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert's syndrome mutations in UGT1A1. Hepatology 33: 627-632.
184. Pluda, J. M., T. P. Cooley, J. S. Montaner, L. E. Shay, N. E. Reinhalter, S. N. Warthan, J. Ruedy, H. M. Hirst, C. A. Vicary, J. B. Quinn, et al. 1995. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171:1438-1447.
185. Podzamczer, D., E. Ferrer, J. M. Gatell, J. Niubo, D. Dalmau, A. Leon, H. Knobel, C. Polo, D. Iniguez, and I. Ruiz. 2005. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir. Ther. 10:171-177.
186. Pommier, Y., A. A. Johnson, and C. Marchand. 2005. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-248.
187. Pugach, P., A. J. Marozsan, T. J. Ketas, E. L. Landes, J. P. Moore, and S.E. Kuhmann. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361: 212-228.
188. Pulido, F., J. R. Arribas, J. M. Miro, M. A. Costa, J. Gonzalez, R. Rubio, J. M. Pena, M. Torralba, M. Lonca, A. Lorenzo, C. Cepeda, J. J. Vazquez, and J.M. Gatell. 2004. Clinical, virologic, and immunologic response to efavirenz or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J. Acquir. Immune Defic. Syndr. 35:343-350.
189. Racoosin, J. A., C. M. Kessler. 1999. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia 5:266-269.
190. Raffi, F., C. Katlama, M. Saag, M. Wilkinson, J. Chung, L. Smiley, and M. Salgo. 2006. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin. Infect. Dis. 42:870-877.
191. Rauch, A., D. Nolan, A. Martin, E. McKinnon, C. Almeida, and S. Mallal. 2006. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. 43:99-102.
192. Ray, N., J. E. Harrison, L. A. Blackburn, J. N. Martin, S. G. Deeks, and R.W. Doms. 2007. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 81:3240-3250.
193. Reeves, J. D., S. A. Gallo, N. Ahmad, J. L. Miamidian, P. E. Harvey, M. Sharron, S. Pohlmann, J. N. Sfaki-anos, C. A. Derdeyn, R. Blumenthal, E. Hunter, and R.W. Doms. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope /coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 99:16249-16254.
194. Rhee, S. Y., M. J. Gonzales, R. Kantor, B. J. Betts, J. Ravela, and R.W. Shafer. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31:298-303.
195. Rhee, S. Y., J. Taylor, G. Wadhera, A. Ben-Hur, D. L. Brutlag, and R.W. Shafer. of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. USA 103:17355-17360.
196. Richman, D. D. 2001. Antiretroviral activity of emtri-citabine, a potent nucleoside reverse transcriptase inhibitor. Antivir. Ther. 6:83-88.
197. Riddler, S. A., Haubrich R., A. G. DiRienzo, L. Peeples, W. G. Powderly, K. L. Klingman, K. W. Garren, T. George, J. F. Rooney, B. Brizz, U. G. Lalloo, R. L. Murphy, S. Swindells, D. Havlir, and J.W. Mellors. 2008. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358:2095-2106.
198. Robbins, G. K., V. De Gruttola, R. W. Shafer, L. M. Smeaton, S. W. Snyder, Pettinelli C., M. P. Dube, M. A. Fischl, R. B. Pollard, R. Delapenha, L. Gedeon, C. van der Horst, R. L. Murphy, M. I. Becker, R. T. D'Aquila, S. Vella, T. C. Merigan, and M.S. Hirsch. 2003. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349:2293-2303.
199. Rodriguez-French, A., J. Boghossian, G. E. Gray, J. P. Nadler, A. R. Quinones, G. E. Sepulveda, J. M. Millard, and P.G. Wannamaker. 2004. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 35:22-32.
200. Rodriguez Novoa, S., P. Barreiro, A. Rendon, A. Barrios, A. Corral, I. Jimenez-Nacher, J. Gonzalez-Lahoz, and V. Soriano. 2006. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435CT polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. 42:291-295.
201. Rotger, M., P. Taffe, G. Bleiber, H. F. Gunthard, H. Furrer, P. Vernazza, H. Drechsler, E. Bernasconi, M. Rickenbach, and A. Telenti. 2005. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192:1381-1386.
202. Ruane, P. J., A. D. Luber, M. B. Wire, Y. Lou, M. J. Shelton, C. T. Lancaster, and K.A. Pappa. 2007. Plasma amprenavir pharmacokinetics and tolerability following administration of 1, 400 milligrams of fosam-prenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antim-icrob. Agents Chemother. 51:560-565.
203. Saag, M. S., P. Cahn, F. Raffi, M. Wolff, D. Pearce, J. M. Molina, W. Powderly, A. L. Shaw, E. Mondou, J. Hinkle, K. Borroto-Esoda, J. B. Quinn, D. W. Barry, and F. Rousseau. 2004. Efficacy and safety of em-tricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 292:180-189.
204. Saag, M. S., A. Sonnerborg, R. A. Torres, D. Lancaster, B. G. Gazzard, R. T. Schooley, C. Romero, D. Kelleher, W. Spreen, S. LaFon, and the Abacavir Phase 2 Clinical Team. 1998. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 12:F203-F209.
205. Sabin, C., S. Worm, R. Weber, W. El-Sadr, P. Reiss, R. Thiebaut, S. DeWit, M. Law, A. Phillips, and J. Lundgren. 2008. Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D Study, abstr. 957c. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
206. Schake, D. 2004. How flexible is tipranavir in complex with the HIV-1 protease active site?. AIDS 18:579-580.
207. Schinazi, R. F., A. McMillan, D. Cannon, R. Mathis, R. M. Lloyd, A. Peck, J. P. Sommadossi, M. St. Clair, J. Wilson, and P.A. Furman. 1992. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2423-2431.
208. Schooley, R. T., P. Ruane, R. A. Myers, G. Beall, H. Lampiris, D. Berger, S. S. Chen, M. D. Miller, E. Isaacson, and A.K. Cheng. 2002. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16:12571263.
209. Schurmann, D., G. Fatkenheuer, J. Reynes, C. Michelet, F. Raffi, J. van Lier, M. Caceres, A. Keung, A. Sansone-Parsons, L. M. Dunkle, and C. Hoffmann. 2007. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 21:1293-1299.
210. Servais, J., J. M. Plesseria, C. Lambert, E. Fontaine, I. Robert, V. Arendt, T. Staub, F. Schneide, R. Hemme, and J.C. Schmit. 2001. Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations. Antivir. Ther. 6:239248.
211. Shafer, R. W., J. M. Schapiro. 2005. Drug resistance and antiretroviral drug development. J. Antimicrob. Chemother. 55:817-820.
212. Shapiro, R. L., I. Thior, P. B. Gilbert, S. Lockman, C. Wester, L. M. Smeaton, L. Stevens, S. J. Heymann, T. Ndung'u, S. Gaseitsiwe, V. Novitsky, J. Makhema, S. Lagakos, and M. Essex. 2006. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 20:1281-1288.
213. Shulman, N. S., R. J. Bosch, J. W. Mellors, M. A. Albrecht, and D.A. Katzenstein. 2004. Genetic correlates of efavirenz hypersusceptibility. AIDS 18:17811785.
214. Smerdon, S. J., J. Jager, J. Wang, L. A. Kohlstaedt, A. J. Chirino, J. M. Friedman, P. A. Rice, and T.A. Steitz. 1994. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 91:3911-3915.
215. Smith, K. Y., W. G. Weinberg, E. Dejesus, M. A. Fischl, Q. Liao, L. L. Ross, G. E. Pakes, K. A. Pappa, and C.T. Lancaster. 2008. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res. Ther. 5:5.
216. Smith, K. Y., D. Fine, P. Patel, N. Bellos, L. Sloan, P. Lackey, D. Sutherland-Phillips, C. Vavro, Q. Liao, and M. Shaefe. 2008. Efficacy and safety of abacavir/lami-vudine combined to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT study, abstr. 774. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
217. Sommadossi, J. P. 1995. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2', 3'-dideoxynucleoside analogues. J. Infect. Dis. 171(Suppl. 2):S88-S92.
218. Spence, R. A., W. M. Kati, K. S. Anderson, and K.A. Johnson. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
219. Squires, K., A. Lazzarin, J. M. Gatell, W. G. Powderly, V. Pokrovskiy, J. F. Delfraissy, J. Jemsek, A. Rivero, W. Rozenbaum, S. Schrader, M. Sension, A. Vibha-gool, A. Thiry, and M. Giordano. 2004. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36:1011-1019.
220. Squires, K. E., R. Gulick, P. Tebas, J. Santana, V. Mu-lanovich, R. Clark, B. Yangco, S. I. Marlowe, D. Wright, C. Cohen, T. Cooley, J. Mauney, K. Uffelman, N. Schoellkopf, R. Grosso, and M. Stevens. 2000. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 14:1591-1600.
221. Staszewski, S., J. Morales-Ramirez, K. T. Tashima, A. Rachlis, D. Skiest, J. Stanford, R. Stryker, P. Johnson, D. F. Labriola, D. Farina, D. J. Manion, and N.M. Ruiz for The Study 006 Team. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med. 341: 1865-1873.
222. Steigbigel, R., P. Kumar, J. Eron, M. Schechter, M. Markowitz, M. Loutfy, J. Zhao, R. Isaacs, B. Y. Nguyen, and H. Teppler. 2008. 48-Week results from BENCHMRK-2, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV, abstr. 789. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
223. Strizki, J. M., C. Tremblay, S. Xu, L. Wojcik, N. Wagner, W. Gonsiorek, R. W. Hipkin, C.-C. Chou, C. Pugliese-Sivo, Y. Xiao, J. R. Tagat, K. Cox, T. Priestley, S. Sorota, W. Huang, M. Hirsch, G. R. Reyes, and B.M. Baroudy. 2005. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49:4911-4919.
224. Su, C., T. Melby, R. DeMasi, P. Ravindran, and G. Heilek-Snyder. 2006. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J. Clin. Virol. 36:249-257.
225. Sulkowski, M., J. Rockstroh, V. Soriano, J. O. Stern, and J. Miki. 2006. Clinical course of increased LFTs and hepatic events associated with ritonavir (RTV) boosted tipranavir (TPV/r) based therapy in the RESIST studies, abstr. H-1899. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
226. Taburet, A. M., C. Piketty, C. Chazallon, I. Vincent, L. Gerard, V. Calvez, F. Clavel, J. P. Aboulker, and P.M. Girard. 2004. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:2091-2096.
227. Taylor, S., D. J. Back, J. Workman, S. M. Drake, D. J. White, B. Choudhury, P. A. Cane, G. M. Beards, K. Halifax, and D. Pillay. 1999. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 13:859-860.
228. Temesgen, Z., J. Feinberg. 2007. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin. Infect. Dis. 45:761-769.
229. Trottier, B., S. Walmsley, J. Reynes, P. Piliero, M. O'Hearn, M. Nelson, J. Montaner, A. Lazzarin, J. Lal-ezari, C. Katlama, K. Henry, D. Cooper, B. Clotet, K. Arasteh, J. F. Delfraissy, H. J. Stellbrink, J. Lange, D. Kuritzkes, J. J. Eron, Jr., C. Cohen, T. Kinchelow, A. Bertasso, E. Labriola-Tompkins, A. Shikhman, B. Atkins, L. Bourdeau, C. Natale, F. Hughes, J. Chung, D. Guimaraes, C. Drobnes, S. Bader-Weder, R. Demasi, L. Smiley, and M.P. Salgo. 2005. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J. Acquir. Immune Defic. Syndr. 40:413-421.
230. Tsibris, M. N., M Sagar, Z. Su, C. Flexner, W. Greaves, P. Skolnik, E. Coakley, M. Subramanian, R. Gulick, and D. Kuritzkes. 2008. Emergence in vivo of vicriviroc resistance in HIV-1 subtype C: role of V3 loop and susceptibility to other CCR5 antagonists, abstr. 870. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
231. Tsiodras, S., C. Mantzoros, S. Hammer, and M. Sa-more. 2000. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch. Intern. Med. 160:2050-2056.
232. Van Gelder, J., S. Deferme, L. Naesens, E. De Clercq, G. van den Mooter, R. Kinget, and P. Augustijns. 2002. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab. Dispos. 30:924-930.
233. van Leth, F., P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, P. Cahn, U. G. Lalloo, I. P. van der Westhuizen, D. R. Malan, M. A. Johnson, B. R. Santos, F. Mulcahy, R. Wood, G. C. Levi, G. Reboredo, K. Squires, I. Cassetti, D. Petit, F. Raffi, C. Katlama, R. L. Murphy, A. Horban, J. P. Dam, E. Hassink, R. van Leeuwen, P. Robinson, F. W. Wit, and J.M. A. Lange for the 2NN Study Team. 2004. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus sta-vudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363:1253-1263.
234. Vibhagool, A., P. Cahn, M. Schechter, F. Smaill, L. Soto-Ramirez, G. Carosi, M. Montroni, C. E. Pharo, J. C. Jordan, N. E. Thomas, and G. Pearce. 2004. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr. Med. Res. Opin. 20:11031114.
235. Vingerhoets, J., H. Azijn, E. Fransen, I. De Baere, L. Smeulders, D. Jochmans, K. Andries, R. Pauwels, and M.P. de Bethune. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782.
236. von Wyl, V., S. Yerly, J. Boni, P. Burgisser, T. Klim-kait, M. Battegay, H. Furrer, A. Telenti, B. Hirschel, P. L. Vernazza, E. Bernasconi, M. Rickenbach, L. Perrin, B. Ledergerber, and H.F. Gunthard. 2007. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch. Intern. Med. 167:1782-1790.
237. Vora, S., A. G. Marcelin, H. F. Gunthard, P. Flandre, H. H. Hirsch, B. Masquelier, A. Zinkernagel, G. Pey-tavin, V. Calvez, L. Perrin, and S. Yerly. 2006. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 20:35-40.
238. Walmsley, S., B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, D. Johnson, R. Lalonde, A. Japour, S. Brun, and E. Sun. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346:2039-2046.
239. Wang, Y., E. Livingston, S. Patil, R. E. McKinney, A. D. Bardeguez, J. Gandia, M. J. O'Sullivan, P. Clax, S. Huang, and J.D. Unadkat. 1999. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J. Infect. Dis. 180:1536-1541.
240. Weinheimer, S., L. Discotto, J. Friborg, H. Yang, and R. Colonno. 2005. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob. Agents Chemother. 49:3816-3824.
241. Westby, M., M. Lewis, J. Whitcomb, M. Youle, A. L. Pozniak, I. T. James, T. M. Jenkins, M. Perros, and E. van der Ryst. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:49094920.
242. Westby, M., C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stockdale, P. Dorr, G. Ciaramella, and M. Perros. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:23592371.
243. Westby, M., E. van der Ryst. 2005. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother. 16:339-354.
244. Wilkin, T. J., Z. Su, D. R. Kuritzkes, M. Hughes, C. Flexner, R. Gross, E. Coakley, W. Greaves, C. Godfrey, P. R. Skolnik, J. Timpone, B. Rodriguez, and R.M. Gulick. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin. Infect. Dis. 44:591-595.
245. Wolinsky, S. M., R. S. Veazey, K. J. Kunstman, P. J. Klasse, J. Dufour, A. J. Marozsan, M. S. Springer, and J.P. Moore. 2004. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 328:19-29.
246. Xu, L., A. Pozniak, A. Wildfire, S. A. Stanfield-Oakley, S. M. Mosier, D. Ratcliffe, J. Workman, A. Joall, R. Myers, E. Smit, P. A. Cane, M. L. Greenberg, and D. Pillay. 2005. Emergence and evolution of enfu-virtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 49:1113-1119.
247. Zhang, D., T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W.G. Humphreys. 2005. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. DrugMetab. Dispos. 33:1729-1739.
248. Zimmermann, A. E., T. Pizzoferrato, J. Bedford, A. Morris, R. Hoffman, and G. Braden. 2006. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin. Infect. Dis. 42:283290.
249. Zingman, B., J. Suleiman, E. DeJesus, J. Slim, M. McCarthy, M. Lee, N. Case, C. Mak, and L. Dunkle. 2008. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results, abstr. 39LB. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.